Laquinimod
drugOn this page
Also known as ABR-215062ABR-215062 FREE ACIDTV-5600 FREE ACIDSID174007071LAQUINIMOD (ABR-215062)
Summary
Laquinimod (CHEMBL66092) is a phase-3 clinical-stage small molecule (ATC N07XX10); indicated across 8 conditions including relapsing-remitting multiple sclerosis and multiple sclerosis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: N07XX10
- Indications: 8 conditions
- Clinical trials: 16
- Chemistry: 356.8 Da · C19H17ClN2O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL66092 |
| Name | Laquinimod |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 54677946 |
| ATC | N07XX10 |
| Molecular formula | C19H17ClN2O3 |
| Molecular weight | 356.8 |
| InChIKey | GKWPCEFFIHSJOE-UHFFFAOYSA-N |
SMILES: CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O
IUPAC name: 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
Also known as: ABR-215062, ABR-215062 FREE ACID, Laquinimod, TV-5600 FREE ACID, SID174007071, LAQUINIMOD, laquinimod, LAQUINIMOD (ABR-215062), Laquinimod (ABR-215062)
Parent form; salt/anhydrous children: CHEMBL2103814
Patent coverage: 855 distinct patent families (3,789 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,770 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| relapsing-remitting multiple sclerosis | 3 | MONDO:0005314 | EFO:0003929 |
| multiple sclerosis | 3 | MONDO:0005301 | MONDO:0005301 |
| Crohn disease | 2 | MONDO:0005011 | EFO:0000384 |
| lupus nephritis | 2 | MONDO:0005556 | EFO:0005761 |
| primary progressive multiple sclerosis | 2 | MONDO:0000451 | EFO:0008520 |
| Huntington disease | 2 | MONDO:0007739 | MONDO:0007739 |
| systemic lupus erythematosus | 2 | MONDO:0007915 | MONDO:0007915 |
| eye disorder | 1 | MONDO:0005328 | EFO:0003966 |
Clinical trials
Total trials: 16.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 8 |
| PHASE3 | 6 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00509145 | PHASE3 | COMPLETED | Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) |
| NCT00605215 | PHASE3 | COMPLETED | BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) |
| NCT00988052 | PHASE3 | TERMINATED | A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course |
| NCT01047319 | PHASE3 | TERMINATED | A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis |
| NCT01707992 | PHASE3 | COMPLETED | The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) |
| NCT01975298 | PHASE3 | WITHDRAWN | A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) |
| NCT00349193 | PHASE2 | COMPLETED | A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod |
| NCT00737932 | PHASE2 | COMPLETED | Laquinimod Phase IIa Study in Active Crohn’s Disease |
| NCT00745615 | PHASE2 | TERMINATED | An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease |
| NCT01085084 | PHASE2 | COMPLETED | A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis |
| NCT01085097 | PHASE2 | COMPLETED | A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis |
| NCT01404117 | PHASE2 | WITHDRAWN | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability |
| NCT02215616 | PHASE2 | COMPLETED | A Clinical Study in Participants With Huntington’s Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod |
| NCT02284568 | PHASE2 | COMPLETED | A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo |
| NCT02085863 | PHASE1 | COMPLETED | A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together |
| NCT05187403 | PHASE1 | COMPLETED | A Study of Laquinimod Eye-drops in Healthy Participants |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).